aerubumab
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 29, 2017 (NCT03027609)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- PseudomonasImmunity, passive
Pseudomonas immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- aerubumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03027609 | Phase 2 | Mar 29, 2017 | Aridis Pharmaceuticals, Inc., Hospital Dupuytren |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aridis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2017 |
| Hospital Dupuytren | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1